Centessa Pharmaceuticals plc (CNTA)
D
Pipeline Grade
Financial Position (from SEC Filings)
$63.1M
Cash & Equivalents
$72.2M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$6,267M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase2 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07598708 | A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central ... | PHASE3 | Recruiting | 222 |
| NCT06752668 | A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia | PHASE2 | Recruiting | 248 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.